| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | -0.035 | 0.8 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.8 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.021 | 0.9 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.034 | 0.9 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.031 | 0.9 |